BACKGROUND: Aspiration pneumonia represents an under-reported complication of chemoradiotherapy in patient with head and neck cancer. The objective of the current study was to evaluate the incidence, risk factors, and mortality of aspiration pneumonia in a large cohort of patients with head and neck cancer who received concurrent chemoradiotherapy. METHODS: Patients who had head and neck cancer diagnosed between 2000 and 2009 were identified from the Surveillance, Epidemiology, and End Results-Medicare database. Aspiration pneumonia was identified from Medicare billing claims. The cumulative incidence, risk factors, and survival after aspiration pneumonia were estimated and compared with a noncancer population. RESULTS: Of 3513 patients with head and neck cancer, 801 developed aspiration pneumonia at a median of 5 months after initiating treatment. The 1-year and 5-year cumulative incidence of aspiration pneumonia was 15.8% and 23.8%, respectively, for patients with head and neck cancer and 3.6% and 8.7%, respectively, for noncancer controls. Among the patients with cancer, multivariate analysis identified independent risk factors (P <.05) for aspiration pneumonia, including hypopharyngeal and nasopharyngeal tumors, male gender, older age, increased comorbidity, no surgery before radiation, and care received at a teaching hospital. Among the patients with cancer who experienced aspiration pneumonia, 674 (84%) were hospitalized; and, of these, 301 (45%) were admitted to an intensive care unit. The 30-day mortality rate after hospitalization for aspiration pneumonia was 32.5%. Aspiration pneumonia was associated with a 42% increased risk of death (hazard ratio, 1.42; P <.001) after controlling for confounders. CONCLUSIONS: The current results indicated that nearly 25% of elderly patients will develop aspiration pneumonia within 5 years after receiving chemoradiotherapy for head and neck cancer. A better understanding of mitigating factors will help identify patients who are at risk for this potentially lethal complication. Cancer 2015;121:1303-11.
INTRODUCTION
Chemoradiation represents a standard treatment approach for locally advanced head and neck cancer. Although the combination of chemotherapy and radiation has a proven survival benefit, it also poses the risk of significant acute and late toxicities that can have a profound impact on survivorship and quality of life among head and neck cancer survivors.
Aspiration pneumonia-defined as pneumonia secondary to inhalation of food particles, saliva, or other foreign substances-represents an under-reported side effect of head and neck cancer after treatment with chemoradiotherapy. 1, 2 Aspiration pneumonia after radiation is likely caused by a combination of contributing factors, including acute and chronic radiation-induced mucosal changes, muscle fibrosis, and xerostomia. 1, [3] [4] [5] [6] These factors lead to swallowing dysfunction, which in turn increases the risk of both aspiration and aspiration pneumonia.
Previous studies characterizing the risk of swallowing dysfunction after radiation have identified dysphagia or aspiration rates ranging from 33% to 81%. 4, [6] [7] [8] Additional research has indicated that aspiration pneumonia is a major source of post-treatment morbidity as well as a potential cause of death among patients with head and neck cancer. 1, 9 The current body of literature on aspiration pneumonia includes single-institution analyses, [7] [8] [9] [10] [11] [12] often with small sample sizes [7] [8] [9] [10] [11] or limited follow-up. 13, 14 To date, population-based studies to characterize the risk of aspiration pneumonia after chemoradiation do not exist. The objective of this study was to use Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data to evaluate the incidence, risk factors, morbidity, and mortality of aspiration pneumonia in a large cohort of patients with head and neck cancer who received concurrent chemoradiotherapy.
MATERIALS AND METHODS

Data Source
In this study, we evaluated patients with head and neck cancer within the SEER-Medicare-linked database. The SEER Program consists of a collection of cancer registries geographically spread across the United States that collect demographic, clinical, treatment, and survival information for individuals with cancer. 15 The Medicare program provides federally funded health insurance for individuals aged 65 years. The SEER-Medicare linkage combines longitudinal Medicare claims data for patients within the SEER database, providing a valuable resource with which to understand patterns of care and health outcomes for cancer patients from before diagnosis and throughout treatment with complete follow-up extending through death.
Aspiration pneumonia represents a known complication among older adults without cancer; therefore, in this study, we compared aspiration pneumonia rates among head and neck cancer patients with the rates in a group of noncancer controls. The noncancer patients were drawn from a 5% random sample of Medicare beneficiaries residing in the same geographic regions covered by SEER. The contents of Medicare files for the noncancer control group were identical to those available for the group of patients with cancer. 15 This study was deemed exempt from approval by the Institutional Review Board at the University of California-San Diego.
Study Population
The initial query of the SEER-Medicare database identified 42,250 patients with head and neck cancer aged >65 years who were diagnosed between 2000 and 2009. Although Medicare coverage starts at age 65 years, only patients aged who were at least 66 were included to ensure that we had a complete year of Medicare claims data to enable the calculation of Charlson comorbidity scores (described below). Patients with invalid dates of diagnosis (n 5 297) and those with nonsquamous cell carcinoma histology (n 5 9326) were excluded. The study cohort was further refined by removing patients who had been diagnosed with multiple primary tumors (n 5 8529) and those who were diagnosed at autopsy or death (n 5 202). Patients who had missing data were excluded (n 5 8642), including those with noncontinuous part A and part B coverage or any part C enrollment (enrollment in a health maintenance organization) from 12 months before diagnosis until death or last follow-up, leaving 15,254 remaining patients. Finally, only patients who had received radiation with concurrent chemotherapy within 6 months of diagnosis were included leaving 3513 cancer patients in the final study cohort.
Study Covariates
Demographic covariates obtained from SEER included patient age at diagnosis, sex, race, and marital status. Geographic location was based on the location of SEER cancer registries, which were categorized into East (Connecticut, New Jersey), Midwest (Detroit, Michigan; Iowa), South (Atlanta, Georgia; rural Georgia; Kentucky; Louisiana), and West (San Francisco, California; Hawaii, New Mexico; Seattle, Washington; Utah; San Jose, California; Los Angeles, California; and Greater California). The median regional household income was determined from year 2000 Census tract data and was divided into quartiles. Patients without household income data (1%) were grouped into the bottom quartile. Tumor site was categorized into 6 groups: oral cavity, nasopharynx, oropharynx and tonsil, larynx, hypopharynx, and other (salivary gland, other oral cavity and pharynx, nose, nasal cavity, and middle ear). The SEER historic staging system 16 was used to classify cancer stage, because TNM staging data was limited for the years studied and was defined differently across head and neck cancer sites. Patients who were staged with "distant" disease according to the historic SEER system for head and neck cancer had locally advanced disease equivalent to T4a and T4b in the American Joint Committee on Cancer staging system. 17 Comorbidity scores were calculated during the year before diagnosis using inpatient and outpatient Medicare claims with the modification of the Charlson comorbidity index reported by Deyo et al. 18 Patient care within a teaching hospital was defined as any indirect medical education charge on a Medicare claim during a hospitalization after the patient's diagnosis of cancer.
Treatment covariates included surgery, radiation, and chemotherapy. Information on whether the patient underwent surgery directed at the primary tumor was obtained from SEER and Medicare billing claims ( 19, 20 Concurrent chemotherapy was defined as a chemotherapy claim anytime from 2 weeks before the start of radiation through 2 weeks after completing radiation. In addition, we assessed for the receipt of additional chemotherapy before (neoadjuvant) or after (adjuvant) the patient received chemoradiotherapy. The use of positron emission tomography (PET) was defined from Medicare claims from 3 months before diagnosis extending through the start of radiation. Intensity-modulated radiation therapy (IMRT) was defined as the existence of any IMRT billing claim during the course of radiation. Table 2 summarizes baseline characteristics of the 3513 patients with head and neck cancer who were included in this study.
Aspiration Pneumonia
Aspiration pneumonia, the primary endpoint of this study, was identified from an International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code of 507.0 (Table 1) , which represents pneumonitis or pneumonia because of inhalation of food or vomitus. 21 The ICD-9 code for aspiration pneumonia is distinct from codes that describe bacterial pneumonia. A study attempting to determine the validity of this ICD-9 code determined that 91% of patients with the ICD-9 code for aspiration pneumonia had objective clinical evidence or a physician note documenting aspiration pneumonia. 22 In the current study, aspiration pneumonia was defined as the presence of ICD-9 diagnosis code 507.0 within inpatient or outpatient Medicare billing claims any time after the start of radiation until the end of the study period (December 31, 2009) or the patient's date of death. Aspiration pneumonia associated with hospitalization was defined as any aspiration pneumonia diagnosis code during a hospitalization. Similarly, admission to an intensive care unit (ICU) was defined as any aspiration pneumonia diagnosis code during admission to an ICU.
Statistical Analysis
The rate of aspiration pneumonia was estimated with a competing risk analysis to account for the competing event of death. The time to an aspiration pneumonia event was defined from the start of radiation through the first aspiration pneumonia claim, censoring at last followup and treating death from any cause as a competing event. Unadjusted estimates of the rate of aspiration pneumonia were determined with nonparametric cumulative incidence functions using Gray's test to compare differences between patients with head and neck cancer and noncancer controls as well as between subgroups among patients with head and neck cancer. 23 Multivariate predictors of aspiration pneumonia were assessed with Fine and Gray regression models to estimate the subdistribution hazards. 24, 25 All covariates were defined a priori based on factors that could have an impact on survival or radiation therapy treatment. All variables that were included in the multivariate model are listed in Table 3 .
We identified noncancer control patients from the Medicare 5% sample using a 1:1 match for noncancer patients who had continuous Medicare parts A and B coverage without part C enrollment for the entire observation period from 2000 to 2009. 26 The match was based on patient characteristics (sex, income, and registry location) as well as age, survival status, and date of death. The time at risk for aspiration pneumonia in the patients with head and neck cancer extended from the start of radiation through death or last follow-up. Noncancer controls did not receive radiation; therefore, a pseudoradiation start date was assigned for controls to ensure an identical at-risk time period to evaluate for aspiration pneumonia. Standardized differences were used to assess the balance between the patients with head and neck cancer and the noncancer controls. The standardized differences for all covariates were-< .02 (data not shown), suggesting an acceptable match.
Kaplan-Meier survival plots and multivariate Cox proportional-hazards models were used to estimate the association of aspiration pneumonia with overall survival. The multivariate Cox model for overall survival included all of the covariates listed in Table 2 . All statistical tests were 2-sided, and P < .05 was considered significant. Analyses were conducted with SAS software (version 9.4; SAS Institute Inc., Cary, NC).
RESULTS
Among the 3513 patients with head and neck cancer in this study, 801 patients developed aspiration pneumonia after radiation, and the median time from the initiation of treatment to an aspiration pneumonia event was 5 months. Among the 3513 matched noncancer controls, 272 developed aspiration pneumonia. The 1-year and 5-year cumulative incidence of aspiration pneumonia was 15.8% (95% confidence interval [CI], 14.6%-17%) and 23.8% (95% CI, 22.3%-25.3%), respectively, for patients with head and neck cancer and 3.6% (95% CI, 3%-4.2%) and 8.7% (95% CI, 7.7%-9.7%), respectively, for the noncancer population as indicated in Figure 1 .
Univariate analysis identified multiple risk factors for aspiration pneumonia, of which select predictors are highlighted in the cumulative incidence plots provided in Figure 2. Multivariate analysis (Table 3) identified multiple independent risk factors for aspiration pneumonia, including increased age, male gender, delivery of care at a teaching hospital, and tumor location in the nasopharynx or hypopharynx. Lower rates of aspiration pneumonia were identified for patients who received treatment in the South (vs the West) and for patients who underwent surgery before receiving radiation. It is noteworthy that disease stage, type of chemotherapy, sequence of chemotherapy with radiation, or the delivery of IMRT did not have an impact on the rate of aspiration pneumonia. Subsequent evaluations focused on the morbidity and mortality associated with aspiration pneumonia. Among the patients with head and neck cancer who experienced aspiration pneumonia, 674 patients (84%) had events associated with hospitalizations that included a 10-day median length of stay. Among those patients who were hospitalized, 301 patients (45%) were admitted to an ICU during their hospitalization. Among the cancer patients who developed aspiration pneumonia, the 30-day mortality rate after developing aspiration pneumonia was 32.5% (Fig. 3A) . The patients with head and neck cancer who experienced aspiration pneumonia had significantly decreased overall survival compared with those who did not have an aspiration event (Fig. 3B) . The 5-year survival rate after diagnosis among those who had aspiration pneumonia was 15.2% versus 32.3% among those without aspiration pneumonia (P < .001). Multivariate analysis controlling for potential confounders indicated that aspiration pneumonia after chemoradiation was associated with a 42% increase in the risk of death (hazard ratio, 1.42; P < .001) compared with the absence of aspiration pneumonia.
DISCUSSION
The current US population-based study demonstrates substantial rates of aspiration pneumonia after concurrent chemotherapy with radiation in older patients with head and neck cancer. Previously reported rates of aspiration pneumonia for patients with head and neck cancer after chemoradiotherapy varied across study populations. A recent single-center study of 324 consecutively treated patients with head and neck cancer from 2006 to 2008 reported that 5.3% of patients developed aspiration pneumonia within the first year after radiation with or without concurrent weekly cisplatin. 12 Eisbruch et al reported that 23% of their 29 patients who received radiation and concurrent gemicitabine developed aspiration pneumonia within 14 months of completing their treatment, 8 whereas Hunter et al reported that 5% of their 72 patients with locally advanced oropharyngeal cancer who received IMRT and carboplatin/paclitaxel developed aspiration pneumonia within 24 months of treatment. 11 A larger, retrospective Taiwanese study of 15,894 patients with head and neck cancer based on insurance claims reported only a 5% incidence of pneumonia, most commonly associated with aspiration, within 3 months of treatment. 13 However, only 15% of those patients were aged >65 years. In the current study, we observed higher rates of aspiration pneumonia than those reported in the study from Taiwan although we identified similar risk factors, such as age, male gender, and hypopharyngeal tumors. The range of incidence rates reported for aspiration pneumonia may be caused by differences in patient characteristics, treatment specifics, followup, and definitions of aspiration pneumonia.
However, aspiration pneumonia is a relatively common event even among older adults without cancer. For elderly patients, the etiology of aspiration likely stems from multiple causes, although data suggest that the progressive age-related loss of protective swallowing reflexes may be contributory. 27 Among patients with head and neck cancer, the etiology of aspiration pneumonia is likely multifactorial; however, radiation-induced dysphagia presumably plays a central role. 28 Radiotherapy can produce fibrosis of the treated pharyngeal tissues, resulting in nerve impairment and muscular injury, and causing generalized weakness and uncoordinated swallowing. In addition, radiation-induced xerostomia reduces salivary flow which could also impair the swallowing mechanism thus increasing the risk of aspiration pneumonia.
Radiation may also represent a unique risk factor for the development of aspiration pneumonia compared with other treatment modalities for head and neck cancer. A recent population-based study of 93,663 patients who underwent surgery for head and neck cancer reported only a 2% rate of aspiration pneumonia. 29 In our study, we also observed a lower risk of aspiration pneumonia for those who underwent surgery before receiving radiation, although these findings may represent selection bias as patients who underwent surgery may have had better overall health, less comorbidity, superior performance status, or more favorable cancer characteristics compared with those who did not undergo surgery. We also identified an increased risk of aspiration pneumonia in patients who received care at a teaching hospital which may reflect differences in unmeasured patient characteristics. Teaching hospitals may care for sicker or more complex patients which could explain the increased risk of aspiration in this subpopulation.
Beyond the increased risk of aspiration with chemoradiotherapy, our study highlights the potential of aspiration pneumonia to substantially impact survival. We observed significantly increased mortality after aspiration pneumonia. Other studies evaluating survival after aspiration pneumonia in patients without cancer have observed similar increases in the risk of death. A recent single-institution, retrospective study of 628 patients with aspiration pneumonia produced a 30-day mortality rate of 21%, although those patients had higher rates of hospitalization and ICU admission (99% and 38%, respectively). 30 Similarly, a multicenter, retrospective cohort study of patients who were admitted with pneumonia indicated that aspiration pneumonia was the greatest risk factor for 30-day mortality with an adjusted hazard ratio of 5.69. 31 The morbidity and potential impact on mortality of aspiration pneumonia after chemoradiotherapy raises the question of whether action can be taken to reduce the risk of this adverse event. Radiation techniques that spare the constrictor muscles involved with swallowing have the potential to reduce dysphagia which is a risk factor for aspiration pneumonia. 32, 33 Prospective studies to reduce the radiation dose in subsets of patients with head and neck cancer are ongoing; hopefully, the decreased radiation dose will reduce toxicity without sacrificing local tumor control. Further research should focus on reducing the volume of tissue electively irradiated in head and neck cancer for patients who have a lower risk of regional tumor spread. Beyond modifying radiation fields, a different approach could concentrate on the preservation of swallowing function with early involvement of speech therapy and rehabilitation among patients at high risk of aspiration. Routine swallowing evaluations to screen for dysphagia among this patient population also may be recommended to select patients who are at risk for this complication. These interventions deserve further study because they stand to potentially improve the survivorship of patients with head and neck cancer.
Although our study characterizes the risk of aspiration pneumonia in a large cohort of patients with head and neck cancer, there are limitations to the presented results. This study population only included patients aged 66 years; therefore, the findings cannot be generalized to a younger patient population. Medicare data are collected for administration purposes; consequently, confounding factors like smoking status, dietary intake, body habitus, and performance status were not collected and could not be analyzed. Similarly, SEER-Medicare data do not include information regarding the doses of chemotherapy or radiotherapy delivered which may have an impact on the rate of aspiration pneumonia. Furthermore, the higher aspiration pneumonia rates in our patient population could have arisen from local cancer progression as opposed to radiation-induced toxicity. However, we observed no correlation between tumor stage and aspiration rates. In addition, this study could not directly assess the accuracy of the primary endpoint of aspiration pneumonia. Although separate diagnosis codes exist for aspiration pneumonia and bacterial pneumonia, distinguishing these 2 diagnoses can pose a clinical challenge with misclassification potentially impacting our findings. Finally, SEER-Medicare data do not contain information on causality; therefore, future studies with additional longitudinal data are required to fully understand what drives the increased risk of aspiration in this cohort of patients.
Overall, this study represents the first US-based population study to define the incidence of aspiration pneumonia in patients with head and neck cancer who received concurrent chemoradiotherapy and to contextualize these results using a matched sample of Medicare beneficiaries without cancer. This work also identified several risk 
